Immunogenic cell death (ICD) is a type of cancer cell death triggered by certain
chemotherapeutic drugs, oncolytic viruses, physicochemical therapies, photodynamic …

In recent years, cancer immunotherapy based on immune checkpoint inhibitors (ICIs) has
achieved considerable success in the clinic. However, ICIs are significantly limited by the …

Programmed death-ligand 1 (PD-L1) is a specialized shield on tumor cells that evades the
immune system. Even inhibited by PD-L1 antibodies, a cycling process constantly transports …

The past decade has witnessed major breakthroughs in cancer immunotherapy. This
development has been largely motivated by cancer cell evasion of immunological control …

Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune
response associated with immunological memory, provided they display sufficient …

Background Immunotherapy represents the future of clinical cancer treatment. The type of
cancer cell death determines the antitumor immune response and thereby contributes to the …

The senescence-associated secretory phenotype (SASP) has recently emerged as a driver
of and promising therapeutic target for multiple age-related conditions, ranging from …

Induction of cell death is inexorably linked with cancer therapy, but this can also initiate
wound-healing processes that have been linked to cancer progression and therapeutic …

Neutrophils are the most abundant leukocytes in the circulation, and have been regarded as
first line of defense in the innate arm of the immune system. They capture and destroy …

Amino acid metabolism is a critical regulator of the immune response, and its modulating
becomes a promising approach in various forms of immunotherapy. Insufficient …